Comparative Pharmacology
Head-to-head clinical analysis: DARVON COMPOUND versus OXYCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON COMPOUND versus OXYCET.
DARVON COMPOUND vs OXYCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Darvon Compound is a combination of propoxyphene, aspirin, and caffeine. Propoxyphene is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing anti-inflammatory and analgesic effects. Caffeine is a CNS stimulant that may enhance analgesia through adenosine receptor antagonism.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Acetaminophen is believed to produce analgesia through central action, possibly mediated through inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways, though the exact mechanism is not fully understood.
One capsule (propoxyphene HCl 65 mg, aspirin 389 mg, caffeine 32.4 mg) orally every 4 hours as needed for pain. Maximum 6 capsules per day.
1 tablet (325 mg acetaminophen and 5 mg oxycodone) orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (terminal, prolonged in overdose due to enterohepatic recirculation). Acetaminophen: 2-3 hours (terminal). Clinical context: accumulation in elderly, hepatic impairment.
The terminal elimination half-life of oxycodone is approximately 3.5-4 hours for immediate-release formulations. For controlled-release formulations, the half-life is similar due to absorption-limited elimination, but the duration of action is extended due to the formulation. In elderly patients or those with hepatic impairment, half-life may be increased up to 2-fold.
Renal: ~70% as unchanged drug and glucuronide conjugates (propoxyphene and acetaminophen). Fecal: <10% as unchanged and metabolites. Biliary: minor route for propoxyphene conjugates.
Oxycodone is primarily metabolized in the liver via CYP3A4 to noroxycodone and via CYP2D6 to oxymorphone. Renal excretion accounts for approximately 87% of the administered dose, with 8.1% as unchanged oxycodone, 22.8% as noroxycodone, 9.1% as noroxymorphone, 3.2% as oxymorphone, and others. Fecal excretion is about 10%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination